• 1
    Bevin TH, Molteno AC, Herbison P. Otago Glaucoma Surgery Outcome Study: long-term results of 841 trabeculectomies. Clin Experiment Ophthalmol 2008; 36: 7317.
  • 2
    Gale J, Wells AP. Medium-term outcomes of safe surgery system trabeculectomies. Br J Ophthalmol 2008; 92: 12325.
  • 3
    Palanca-Capistrano AM, Hall J, Cantor LB, Morgan L, Hoop J, WuDunn D. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology 2009; 116: 18590.
  • 4
    Georgoulas S, Dahlmann-Noor A, Brocchini S, Khaw PT. Modulation of wound healing during and after glaucoma surgery. Prog Brain Res 2008; 173: 23754.
  • 5
    Grimm D, Bauer J, Schoenberger J. Blockade of neoangiogenesis, a new and promising technique to control the growth of malignant tumors and their metastases. Curr Vasc Pharmacol 2009; 7: 34757.
  • 6
    Jain L, Vargo CA, Danesi R et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009; 8: 2496508.
  • 7
    Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Res C Embryo Today 2003; 69: 36374.
  • 8
    Schlingemann RO, Witmer AN. Treatment of retinal diseases with VEGF antagonists. Prog Brain Res 2009; 175: 25367.
  • 9
    Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009; 153: 34758.
  • 10
    Gordon CR, Rojavin Y, Patel M et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009; 62: 7079.
  • 11
    August DA, Serrano D, Poplin E. 'Spontaneous' delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 2008; 97: 1805.
  • 12
    Li Z, Van Bergen T, Van de Veire S et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2009; 50: 521725.
  • 13
    O'Neill EC, Qin Q, Van Bergen NJ et al. Anti-fibrotic activity of bevacizumab on human tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci 2010; 51: 652432.
  • 14
    Grewal DS, Jain R, Kumar H, Grewal SP. Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 2008; 115: 21415.
  • 15
    Memarzadeh F, Varma R, Lin LT et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. Invest Ophthalmol Vis Sci 2009; 50: 32337.
  • 16
    How A, Chua JL, Charlton A et al. Combined treatment with bevacizumab and 5-fluorouracil attenuates the postoperative scarring response after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2010; 51: 92832.
  • 17
    Sengupta S, Venkatesh R, Ravindran RD. Safety and efficacy of using off-label bevacizumab versus mitomycin C to prevent bleb failure in a single-site phacotrabeculectomy by a randomized controlled clinical trial. J Glaucoma 2012; 21: 4509.
  • 18
    Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Am J Ophthalmol 2010; 150: 399403.
  • 19
    Sedghipour MR, Mostafaei A, Taghavi Y. Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma. Clin Ophthalmol 2011; 5: 797800.
  • 20
    Jurkowska-Dudzińska J, Kosior-Jarecka E, Zarnowski T. Comparison of the use of 5-FU and bevacizumab in primary trabeculectomy: results at one year. Clin Experiment Ophthalmol 2012; 40: e13542.
  • 21
    Nilforushan N, Yadgari M, Kish SK, Nassiri N. Subconjunctival bevacizumab versus mitomycin C adjunctive to trabeculectomy. Am J Ophthalmol 2012; 153: 3527.e1.
  • 22
    Wells AP, Crowston JG, Marks J et al. A pilot study of a system for grading of drainage blebs after glaucoma surgery. J Glaucoma 2004; 13: 45460.
  • 23
    Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010; 21: 11217.
  • 24
    Mathew R, Barton K. Anti-vascular endothelial growth factor therapy in glaucoma filtration surgery. Am J Ophthalmol 2011; 152: 1015.
  • 25
    Kahook MY, Schuman JS, Noecker RJ. Needle bleb revision of encapsulated filtering bleb with bevacizumab. Ophthalmic Surg Lasers Imaging 2006; 37: 14850.
  • 26
    Kapetansky FM, Pappa KS, Krasnow MA et al. Subconjunctival injection(s) of bevacizumab for failing filtering blebs. [E-Abstract 837]. Invest Ophthalmol Vis Sci 2007; 48: 837.
  • 27
    Purcell JM, Teng CC, Tello C et al. Effect of needle bleb revision with ranibizumab as a primary intervention in a failing bleb following trabeculectomy. [E-Abstract 4165]. Invest Ophthalmol Vis Sci 2008; 49: 4165.
  • 28
    Coote MA, Ruddle JB, Qin Q, Crowston JG. Vascular changes after intra-bleb injection of bevacizumab. J Glaucoma 2008; 17: 51718.
  • 29
    Yu JY, Kahook MY, Schuman JS et al. Bevacizumab binding to human sclera post topical application. [E-Abstract 4815]. Invest Ophthalmol Vis Sci 2007; 48: 4815.
  • 30
    Nomoto H, Shiraga F, Kuno N et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 480713.
  • 31
    Kamba T, Tam BYY, Hashizume H et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult vasculature. Am J Physiol Heart Circ Physiol 2006; 290: 56076.
  • 32
    Hamrah P, Chen L, Cursiefen C, Zhang Q, Joyce NC, Dana MR. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Exp Eye Res 2004; 79: 55361.
  • 33
    Sharma RK, Rogojina AT, Chalam KV. Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF. Mol Vis 2010; 16: 217584.
  • 34
    Ko J, Ross J, Awad H, Hurwitz H, Klitzman B. The effects of ZD6474 an inhibitor of VEGF signaling, on cutaneous wound healing in mice. J Surg Res 2005; 129: 2519.
  • 35
    Loscalzo J, Kohane I, Barabasi AL. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007; 3: 12434.